肿瘤及自体免疫药物的开发商嘉和生物药业(06998.HK)于周二(12月30日)发布公告,与生物制药公司亿腾医药集团自2024年9月推进合并,后者通过反方向形式收购或借壳,视作重新上市,已于今(12月30日)早正式生效,并正式易名为亿腾嘉和(06998.HK),成为在香港首家生物医药或科技公司完成借壳合并的交易。该集团亦同时易名为亿腾嘉和医药集团,集团的总股本数目已由原有逾5.28亿股,增至...
Source Link肿瘤及自体免疫药物的开发商嘉和生物药业(06998.HK)于周二(12月30日)发布公告,与生物制药公司亿腾医药集团自2024年9月推进合并,后者通过反方向形式收购或借壳,视作重新上市,已于今(12月30日)早正式生效,并正式易名为亿腾嘉和(06998.HK),成为在香港首家生物医药或科技公司完成借壳合并的交易。该集团亦同时易名为亿腾嘉和医药集团,集团的总股本数目已由原有逾5.28亿股,增至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.